Skip to content

Study · Not a test of the peptide alone · 1999

2 results

Expression of melanocortin receptors and pro-opiomelanocortin in the rat spinal cord in relation to neurotrophic effects of melanocortins.

van der Kraan M, Tatro JB, Entwistle ML, Brakkee JH, Burbach JP, Adan RA, Gispen WH

Brain research. Molecular brain research1 Jan 1999Cited by 53 (Europe PMC)

PMID9878783 (opens in a new tab)DOI10.1016/s0169-328x(98)00291-5 (opens in a new tab)PepBankPUB-09878783
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Mechanism

    In rat spinal cord, 125I-NDP-MSH binding showed melanocortin receptor protein, mainly in substantia gelatinosa and area X around the central canal.

    In plain wordsIn rats, a labeled form of NDP-MSH showed melanocortin receptors in certain spinal cord regions.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableMC receptor protein in rat spinal cord (125I-NDP-MSH binding)
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    In situ binding studies using 125I-NDP-MSH, a synthetic alpha-MSH analogue, demonstrated MC receptor protein in the rat spinal cord, predominantly localised in substantia gelatinosa and area X, surrounding the central canal.
    1 context sentence
    Summary · context
    To identify candidate components of the signaling system that may mediate these effects, in the present study rat spinal cord, dorsal root ganglia, sciatic nerve and soleus muscle were analysed for the expression of the neural MC3, MC4 and MC5 receptors and for the expression of the melanocortin pre…

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Mechanism

    In rats, subtle changes in melanocortin receptor binding occurred after surgery in several spinal cord regions, in both sham-operated and sciatic nerve-lesioned rats.

    In plain wordsIn rats, receptor binding changed slightly after surgery in several spinal cord regions, in sham and nerve-injured animals alike.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Direction not reportedMC receptor binding after surgery in spinal cord
    Study

    ratn: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Nevertheless, subtle changes in melanocortin receptor binding did occur postsurgically in several regions of the spinal cord in both sham-operated and sciatic nerve-lesioned rats.
    1 context sentence
    Summary · context
    To identify candidate components of the signaling system that may mediate these effects, in the present study rat spinal cord, dorsal root ganglia, sciatic nerve and soleus muscle were analysed for the expression of the neural MC3, MC4 and MC5 receptors and for the expression of the melanocortin pre…

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.